Telomeres Length in Israeli Fibrotic ILD Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

leukocyte telomere length (LTL) will be measured using the Telomere Restriction Fragment (TRF) Analysis method: Peripheral blood leukocytes telomere length will be measured both by TRF analysis and by Nanopore sequencing. Both analyses will be conducted at the laboratory of Prof. Yehuda Tzfati at the Hebrew University, which is highly experienced in the field of telomere biology and in telomere length analysis. Blood samples will be taken once from each participant. No genetic sequencing will be performed as part of this study.

Study summary

Individuals with fibrotic interstitial lung diseases (FILD) will be recruited after providing informed consent. in addition to routine data as usually collected in the clinic, blood samples will be taken for measurement of telomeres length in peripheral blood leukocytes using both the Telomere Restriction Fragment (TRF) Analysis method and Nanopore sequencing. Participants with FILD will be followed-up for 2-year after recruitment, including clinical and pulmonary function tests at-least every 6 months, or more frequently, according to the treating physician discretion.

Eligibility

Primary outcome measure(s)

• the prevalence of short LTL among Israeli patients with familial and sporadic FILD. — 1 year
  the prevalence of short LTL among Israeli patients with familial and sporadic FILD.

Trial sites (2)

More Barzilai Medical Center trials in Israel

Other trials for the same condition